Peter Maag

Peter Maag is a distinguished professional with a track record of driving significant growth through innovative product strategies, creative licensing agreements, and astute investment tactics in the pharmaceuticals and diagnostics industries across multiple continents.

His expertise lies in general management, commercial operations, strategy, business development, and licensing agreements (BD&L), where he has excelled in fostering customer-centric approaches, enhancing performance management, and spearheading product innovation in pharmaceuticals and molecular diagnostics.

With a robust educational background including a PhD in Healthcare from Humboldt-Universität zu Berlin, a Master's degree in Pharmacy from Ruprecht-Karls-Universität Heidelberg, and additional studies at the School of Pharmacy, University of London, Peter Maag has honed a deep understanding of the healthcare industry.

Throughout his career, Peter Maag has held prominent leadership positions, such as President and CEO at CareDx, Inc, President Diagnostics at Novartis, Country Head CEO in both Germany and Korea at Novartis, Head of Business Franchise Infectious Diseases at Novartis, and Board Member at MolecularMD.

His tenure at McKinsey & Co as an Associate Principal and as the Head of Strategy at Novartis has further enriched his professional acumen, making him adept at building organizations, leading companies through transitions, and inspiring global teams to achieve exceptional results.

Peter Maag is known for his passion, authenticity, and ability to mobilize teams towards success, making him a valuable asset in any leadership role within the pharmaceutical and diagnostics sectors.